How much funding has Galera Therapeutics raised?

Galera Therapeutics has raised $203.0M in total funding, most recently a Series C round.

Who are Galera Therapeutics's investors?

Galera Therapeutics's investors include New Enterprise Associates, Novartis Venture Fund, Novo Holdings A/S, Clarus Ventures, Correlation Ventures, Adage Capital.

When was Galera Therapeutics founded?

Galera Therapeutics was founded in 2009.

Where is Galera Therapeutics headquartered?

Galera Therapeutics is headquartered in Malvern.

What industry is Galera Therapeutics in?

Galera Therapeutics operates in Biotech, Healthcare.

How many employees does Galera Therapeutics have?

Galera Therapeutics has 1-10 employees.

Galera Therapeutics

IPO

Transforming the science and treatment of cancer.

Public · Malvern · Founded 2009 · $203.0M raised

Biotech

Healthcare

Headquarters: Malvern
Employees: 1–10
Founded: 2009
Business Model: B2B
Website: galeratx.com

Total Funding: $203.0M
Last Round: $150.0M Series CSep 2018
Rounds: 3
Type: Public

About

Galera Therapeutics is a clinical-stage biopharmaceutical company pioneering novel small molecules that target critical vulnerabilities in cancer cells, immune cells, and the tumor microenvironment. Based in Malvern, Pennsylvania, Galera focuses on improving the anti-cancer efficacy of current therapies, particularly for patients with breast cancer.

Summary

Galera Therapeutics is a Biotech company based in Malvern, founded in 2009. It has raised $203.0M in total across 3 rounds, most recently a $150.0M Series C round in Sep 2018. Investors include New Enterprise Associates, Novartis Venture Fund and Novo Holdings A/S.

LinkedIn X (Twitter)